Centiva Capital’s Travere Therapeutics TVTX Stock Holding History

Centiva Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-34,041	Closed	-$304K	–	2261
2023 Q3	$304K	Buy	+34,041	New	+$480K	0.01%	1164

Other funds holding TVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Centiva Capital's TVTX Position: Q4 2023 in Review

Centiva Capital sold out of Travere Therapeutics (TVTX) in Q4 2023, closing a stake of 34,041 shares — an estimated $304K sold.

Centiva Capital first reported a position in TVTX in Q3 2023 and held it in 1 quarter. The position peaked at $304K in Q3 2023. 165 funds tracked by Wall St. Rank hold TVTX as of Q4 2023.

Centiva Capital reported no remaining Travere Therapeutics position as of Q4 2023 after selling out during the quarter.
Centiva Capital sold 34,041 Travere Therapeutics shares in Q4 2023, an estimated $304K.
Centiva Capital first reported a position in Travere Therapeutics in Q3 2023 and held it in 1 quarter.
Centiva Capital's Travere Therapeutics position peaked at $304K in Q3 2023.
165 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.